Class Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for Investors - Contact The Gross Law Firm

Core Viewpoint - Altimmune, Inc. faced significant stock price decline following the announcement of disappointing results from its IMPACT Phase 2b MASH trial, leading to a class action notice for shareholders [1][2]. Group 1: Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [1]. - The stock price of Altimmune dropped from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [1]. Group 2: Shareholder Actions - Shareholders who purchased shares of ALT during the class period from August 10, 2023, to June 25, 2025, are encouraged to register for potential lead plaintiff appointment in the class action [1][2]. - The deadline for shareholders to seek lead plaintiff status is October 6, 2025, and there is no cost or obligation to participate in the case [2]. Group 3: Legal Representation - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].